echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > New rules for marketing authorization holders open for comments! There are special requirements for the audit of pharmaceutical packaging material suppliers and the post-marketing change control system of drugs

    New rules for marketing authorization holders open for comments! There are special requirements for the audit of pharmaceutical packaging material suppliers and the post-marketing change control system of drugs

    • Last Update: 2022-12-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On November 29, the State Food and Drug Administration (NMPA) publicly solicited comments on the Provisions on the Implementation of the Supervision and Administration of Drug Quality Subject Responsibility by Drug Marketing Authorization Holders (Draft for Comments) (the Draft for Comments), with a deadline of December 9
    , 2022.
    The Draft aims to further strengthen the holder's main responsibility for quality throughout the life cycle, and it emphasizes that the holder should comply with the Drug Administration Law of the People's Republic of China and other relevant laws and regulations, establish and improve the drug quality management system in accordance with the requirements of good manufacturing practice, good management practice for drug trading, and pharmacovigilance quality management practice, and conduct drug development, production, and operation in accordance with the law.
    Responsible
    for the safety, effectiveness and quality controllability of the whole process of use.
    The Draft further clarifies the responsibilities of key personnel and summarizes the responsibilities and qualification requirements of key positions of holders
    .
    At the same time, the new requirements and new systems of quality management are also summarized and emphasized, emphasizing the effective operation of the holder's quality management system, clarifying the working mechanism that the holder should establish to implement the main responsibility of quality, and forming an effective guarantee
    for the quality and safety of drugs.
    Among them, Article 13 [Requirements for the Management of Raw and Auxiliary Packaging] puts forward special requirements
    for the audit of pharmaceutical packaging material suppliers.

    Article 13 [Requirements for the Management of Raw and Auxiliary Packaging] The holder shall audit suppliers of raw materials, auxiliary materials, packaging materials and containers that directly contact drugs, and ensure that the raw materials, auxiliary materials, packaging materials and containers that are in direct contact with drugs purchased and used meet the requirements for medicinal use, and comply with the relevant requirements of quality management specifications formulated by the drug regulatory department under the State Council and the corresponding related review and approval, as well as the requirements
    of laws and regulations.

    Article 14 [Change Management Requirements] puts forward requirements
    for the establishment of a post-marketing change control system for drugs.

    Article 14 [Change Management Requirements] The holder shall establish a post-marketing change control system for drugs in accordance with the relevant provisions on drug supervision and the requirements of good manufacturing practices, formulate and implement internal change classification principles, change items, work procedures, and risk management requirements, and determine the change management category after full research, evaluation, and necessary verification in combination with product characteristics, and implement it after approval, filing, or indicate it in the annual report
    .


    Where production is commissioned, relevant research, evaluation and necessary verification
    shall be carried out jointly with the entrusted production enterprise.

    In addition, Article 23 [Requirements for Drug Safety Incidents] stipulates that in the event of a safety incident related to drug quality, the holder shall immediately take effective measures to dispose of the relevant drugs and their raw materials, excipients, packaging materials and containers and relevant production lines that directly contact drugs, so as to prevent the harm from expanding
    .

    For details, please click [Read Original] to view
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.